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Abstract
Purpose—Lung squamous cell carcinoma (LSCC) currently lacks effective targeted therapies.
Previous studies reported overexpression of HEDGEHOG (HH)-GLI signaling components in
LSCC. However, they addressed neither the tumor heterogeneity nor the requirement for HH-GLI
signaling. Here, we investigated the role of HH-GLI signaling in LSCC, and studied the
therapeutic potential of HH-GLI suppression.
Experimental Design—Gene expression datasets of two independent LSCC patient cohorts
were analyzed to study the activation of HH-GLI signaling. Four human LSCC cell lines were
examined for HH-GLI signaling components. Cell proliferation and apoptosis were assayed in
these cells after blocking the HH-GLI pathway by lentiviral-shRNA knockdown or small molecule
inhibitors. Xenografts in immunodeficient mice were used to determine the in vivo efficacy of GLI
inhibitor GANT61.
Results—In both cohorts, activation of HH-GLI signaling was significantly associated with the
classical subtype of LSCC. In cell lines, genetic knockdown of SMO produced minor effects on
cell survival, while GLI2 knockdown significantly reduced proliferation and induced extensive
apoptosis. Consistently, the SMO inhibitor GDC-0449 resulted in limited cytotoxicity in LSCC
cells, whereas the GLI inhibitor GANT61 was very effective. Importantly, GANT61 demonstrated
specific in vivo anti-tumor activity in xenograft models of GLI-positive cell lines.
Conclusion—Our studies demonstrate an important role for GLI2 in LSCC, and suggest GLI
inhibition as a novel and potent strategy to treat a subset of LSCC patients.
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Introduction
Lung cancer is the leading cause of cancer-related death worldwide. Squamous cell
carcinoma (LSCC) comprises ∼30% of non-small cell lung cancers and is associated
strongly with smoking. Although oncogenic alterations have been gradually described in
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LSCC, druggable targets have not been identified, resulting in lack of effective targeted
therapies (1). Analysis of gene expression of resected tumors has classified LSCC into four
mRNA expression subtypes, defined as classical, primitive, secretory and basal (2). The
oncogenic drivers and potential cells of origin of tumors within these subtypes are likely
different (2, 3). However, the practical application of these expression subtypes in clinical
care has not been determined.
Recently, growing evidence has suggested aberrant activation of the HEDGEHOG (HH)
signaling pathway in lung cancer, which plays a critical role during lung development (4, 5).
Canonical HH signaling is initiated by the binding of HH ligands (SONIC, INDIAN and
DESERT HEDGEHOG) to a 12-transmembrane receptor PATCHED (PTCH), which
relieves the catalytic inhibition of SMOOTHENED (SMO), a 7-transmembrane G-protein
coupled receptor (GPCR)-like signal transducer. SMO de-repression triggers a series of
intracellular events, resulting in the activation of downstream target genes through the zinc-
finger transcription factors GLI1, GLI2 and GLI3 (6). GLI activation is complex with
regulation at both the transcriptional and post-translational levels (7). GLI2 appears to be the
primary activator of HH signaling in cancer, with GLI1 as a transcriptional target of GLI2
(8-10). GLI2 and GLI1 also induce transcription of overlapping and distinct sets of
downstream targets (11). Several components of the HH pathway (PTCH, GLI1, GLI2,
HHIP) are GLI transcriptional targets that induce positive or negative feedbacks (7). GLI
targets mediate various cellular responses, notably enhanced cell proliferation and survival
by upregulating D-type cyclins and anti-apoptotic proteins (12-14). Finally,
phosphatidylinositol 3-kinase (PI3K)/AKT and RAS-MEK signals have been described as
non-canonical HH activators in cancer (15-17).
Dysregulation of the HH pathway has been implicated in a variety of cancers (18). Although
the involvement of HH signaling in small-cell lung cancer is well established (4, 5), the role
of this pathway in non-small cell lung cancer remains poorly understood. However, multiple
lines of evidence point to the potential importance of HH signaling in LSCC.
Immunohistochemical studies in patient specimens reported the overexpression of HH
signaling components (19, 20). Microarray analysis identified hyperactive HH signaling in
LSCC (21). HH-GLI signaling has also been implicated in squamous cancer of other organs
(22-24) . Despite these studies, very little is known regarding the specific role of HH
signaling in regulating cellular survival and proliferation in LSCC.
Targeted inhibitors of the HH pathway have become available recently. Because of its
accessibility on the membrane and its importance in regulation of the pathway, SMO has
been the primary focus in the development of small molecule inhibitors of the HH pathway.
GDC-0449 (vismodegib; Genentech) is an orally administered agent that selectively
suppresses SMO activity and was the first SMO inhibitor to progress to clinical trials. It has
produced promising antitumor responses in patients with advanced basal cell carcinoma and
medulloblastoma (25, 26), but resistance has been reported (27, 28). The resistance to SMO
inhibitors highlights the therapeutic need to target downstream effectors to maintain robust
on-target responses. In a cell-based screen of GLI-mediated transcription (29), the small
molecule GANT61 was identified as a specific inhibitor of GLI1 and GLI2. It suppresses the
DNA binding capacity of GLIs and inhibits GLI-mediated transcription. GANT61 reduces
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proliferation and induces apoptosis in a GLI-specific fashion in prostate cancer (29), colon
carcinoma (30, 31), oral squamous cell carcinoma (23), pancreatic cancer (32),
neuroblastoma (33), and chronic lymphocytic leukemia (34). In this study, we investigate
the role of HH-GLI signaling in LSCC and assess the clinical feasibility of using GDC-0449
or GANT61 to treat LSCC.
Materials and Methods
RNAseq and microarray analysis
RSEM values (35) for 178 tumor samples from The Cancer Genome Atlas (TCGA) LSCC
study (3) were converted to expression measurements by replacing values equal to zero with
the smallest non-zero value, taking a log2 transformation. After median centering by gene,
heatmaps of the expression values from TCGA (3) and microarray data from 56 LSCC
samples collected at the University of North Carolina (2) (UNC cohort) were produced with
R 2.15.1 (36) and the gplots package. Hypotheses were subsequently tested: One-sided
Wilcoxon Rank Sum tests were used to test the null hypothesis that the mean expression
levels of PTCH1, GLI1, GLI2, GLI3, and SUFU are the same in the classical subtype as all
other subtypes combined. For PTCH1, GLI1, and GLI2, the alternative hypothesis was that
the expression levels are higher in the classical subtype, whereas for GLI3 and SUFU the
alternative hypothesis was that the expression levels are lower in the classical subtype. A
Bonferroni adjustment was applied to correct for multiple comparisons.
Two-sided Wilcoxon Rank Sum tests were used to test the null hypothesis that GLI1 and
GLI2 expression values were equal in the TCGA and UNC cohorts. Spearman correlation
coefficients were computed based on the uncentered expression values of GLI1, GLI2,
TP63, PIK3CA, and SOX2 in both cohorts. The resulting unadjusted p values were used to
assess the significance of these associations (Supplementary Table 2).
Gene expression data from 20 LSCC cell lines was obtained from the Cancer Cell Line
Encyclopedia (CCLE) (37). After median centering the expression values by gene, the
centroid classifier from (2) was used to predict expression subtypes for each line by finding
the nearest centroid using a distance metric equal to one minus the Pearson correlation
coefficient. Gene expression heatmaps were then produced using R2.15.1 (36) and the gplots
package.
Cell culture and reagents
NCI-H520, NCI-H2170, NCI-H226 and SK-MES-1 cells were obtained from ATCC. Cell
lines were routinely verified by morphology and growth characteristics, and verified
biannually to be mycoplasma-free. NCI-H520, NCI-H2170 and NCI-H226 cells were
maintained in the RPMI 1640 medium containing 10% FBS. SK-MES-1 cells were
maintained in MEM medium containing 10% FBS, 0.1 mM non-essential amino acids, 1.0
mM sodium pyruvate. Antibodies: SHH, PTCH, SMO (Santa Cruz); GLI2, GAPDH
(Abcam); GLI1 (Novus Biologicals); Cleaved Caspase-3, Cleaved PARP (Cell Signaling
Technology); CCND1 (BD Biosciences). Compounds: GANT61 (Sigma) and GDC-0449
(Chemietek).
Huang et al. Page 3






















Lentiviral production and transduction
Lentiviral shRNA clones (Sigma Mission RNAi) targeting SMO, GLI2 and the non-
targeting control (SHC002) were purchased from Sigma-Aldrich. 293T cells were plated in
10-cm plates 24 hours prior to transfection in DMEM medium containing 10% FBS without
antibiotics. 5 μg shRNA plasmid, 4 μg psPAX2 and 1 μg pCI-VSVG packaging vectors
(Addgene) were co-transfected into 293T cells using Lipofectamine 2000 Reagent
(Invitrogen). Viral supernatants were collected, centrifuged and filtered with 0.45 μm PES
Sterile Syringe Filter. Target cells were plated and incubated at 37°C, 5% CO2 overnight,
and changed to medium containing lentivirus and 8 μg/mL polybrene. Control plates were
incubated with medium containing 8 μg/mL polybrene. Cells were changed to fresh culture
medium 24 hours after infection. Puromycin selection (5 μg/ml) was started 48 hours post
infection and continued for 4∼5 days until no viable cells were observed in control plates.
Once decreased expression of the targeted gene was confirmed, cells were used for
subsequent experiments. Stable expression of non-targeting control, SMO or GLI2 shRNAs
was ensured by culturing cells in the presence of puromycin.
The shRNA sequences:
SMO sh1 (5′- CCGGCCTGATGGACACAGAACTCATCTCGAGATGAGTTCTG
TGTCCATCAGGTTTTT-3′)
SMO sh2 (5′- CCGGCATCTTTGTCATCGTGTACTACTCGAGTAGTACACGA
TGACAAAGATGTTTTT-3′)
SMO sh3 (5′- CCGGGTGGAGAAGATCAACCTGTTTCTCGAGAAACAGGTTG
ATCTTCTCCACTTTTT-3′)






Assessment of cell viability and caspase 3/7 activity
Cell viability and caspase 3/7 activity were determined by using ApoLive-Glo Multiplex
Assay (Promega) according to the manufacturer's instructions. Briefly, cells were seeded in
96-well clear-bottom white plates at a density of 10,000 cells per well and incubated with
complete medium overnight at 37°C, 5% CO2. The following day, cells were changed into
0.5% FBS-containing medium with either DMSO control or drugs at designated
concentrations (0.1% final DMSO concentration) as triplicates and treated for 96 hours. At
the end of treatment, viability reagent was added into all wells and gently mixed. After 1.5-
hour incubation at 37°C, fluorescence was measured at the wavelength set 355EX/ 520EM by
a FLUOstar Omega Microplate reader. Later, Caspase-Glo® 3/7 Reagent was added to all
wells and gently mixed. Luminescence was measured after 1-hour incubation at room
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temperature. The reading of blank control was subtracted from readings of other wells as the
background in the data analysis.
RNA isolation and quantitative PCR
Total RNA was isolated using the Qiagen RNeasy Mini Kit, treated with DNase I
(Invitrogen) and converted to cDNA using iScript cDNA Synthesis Kit (BIO-RAD). Real-
time PCR was performed using TaqMan Gene Expression Master Mix on an Eppendorf
Mastercycler, and raw data were analyzed by Realplex software. TaqMan probes for SHH,
PTCH1, SMO, GLI1, GLI2, HHIP and GAPDH were purchased from Applied Biosystems.
Western analysis
Total cellular lysates were prepared by using RIPA buffer (Sigma) with protease inhibitor
cocktail (Sigma) and PhosSTOP (Roche). Protein concentrations were determined by Micro
BCA Protein Assay Kit (Thermo Scientific). Proteins were separated on the NuPAGE
4-12% Bis-Tris Gel (Life Technologies) and transferred using Invitrolon PVDF Filter Paper
Sandwich. Membranes were blocked with 5% nonfat dry milk or 5% BSA in 0.1%TBST for
1 hour in room temperature, then incubated with primary antibody overnight at 4°C. They
were subsequently washed with 0.1%TBST and incubated with the secondary antibody for 1
hour at room temperature. Western Lightning- ECL (PerkinElmer) was used to develop the
membranes.
Xenograft and tumor treatment
106 NCI-H520 cells, 106 NCI-H2170 cells or 5×106 NCI-H226 cells were suspended in a
total volume of 100 μl of a 1:1 mixture of RPMI 1640 medium: Matrigel (BD Biosciences).
Cells were injected subcutaneously in the right posterior flank of 6∼8 week C.129S7 (B6)-
Rag1tm1Mom/ J (Rag1-/-) mice. Tumors were grown until they reached a median size of
≈250 mm3 (NCI-H520), ≈230 mm3 (NCI-H2170), and ≈150 mm3 (NCI-H226). Animals
were randomly divided into groups and treated with solvent only (corn oil: ethanol, 4:1) or
GANT61 in solvent (50 mg/kg). Treatments were given every other day for 20 days by
intraperitoneal injection. Tumor volumes were calculated by the formula 0.52×length×
(width)2. At the end of treatment, tumors were removed, weighed and processed for
subsequent analysis. All animal experiments were approved by and conformed to the
policies and regulations of Institutional Animal Care and Use Committees at Duke
University.
Results
Activation of HH-GLI signaling is associated with the classical subtype of human LSCC
To ascertain whether HH signaling is upregulated in a particular subset of LSCC patients,
the RNA expression data of 178 patient samples from the Cancer Genome Atlas (TCGA)
LSCC study (3) was queried. As Figure 1A demonstrates, the expression of HH target genes
(PTCH1, GLI1, GLI2) was significantly higher, while expression of negative regulators
(GLI3, SUFU) was substantially lower in the classical subtype in comparison to the other
subtypes. One-sided Wilcoxon Rank Sum Test confirmed these observations
(Supplementary Table 1) even after applying a Bonferroni adjustment for multiple
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comparisons. Similar expression patterns were seen in an independent cohort of 56 LSCC
samples collected at the University of North Carolina (2) (UNC cohort) (Supplementary
Figure S1A). In both cohorts, GLI2 mRNA level was significantly higher than GLI1 (Figure
1B, Supplementary Figure S1B). Samples with high GLI2 expression were mainly found in
the classical subtype although occasionally in other subtypes. When taking the 75th
percentile of all GLI2 expression values in a given cohort as the threshold for high GLI2,
55% (TCGA cohort) and 52% (UNC cohort) of all classical subtype samples exhibited high
GLI2 expression (Figure 1C, Supplementary Figure S1C).
Strong positive correlations between GLI2 and the prominent markers for the classical
subtype (SOX2, TP63 and PIK3CA) on chromosome 3q were observed in both cohorts
(Figure 1D∼F, Supplementary Figure S1D∼F). However, GLI1 was only associated with
classical chr3q genes in the TCGA cohort (Supplementary Figure S1G∼I), suggesting that
GLI2 is highly likely to be the major signaling transducer in LSCC. Spearman correlation
coefficients between GLI2/ GLI1 and the classical subtype markers with corresponding p
values were provided in Supplementary Table 2.
HH-GLI signaling components are expressed in human LSCC cell lines
The difficulty of growing human LSCC cells in vitro limits available primary cancer cells.
Therefore, we chose the four most widely used human LSCC cell lines to analyze active HH
signaling: NCI-H520 and NCI-H2170, derived from primary tumors; and NCI-H226 and
SK-MES-1, derived from metastatic pleural effusions. By real-time PCR (Figure 2A) and
Western blots (Figure 2B), high levels of SHH were detected only in NCI-H520, whereas
PTCH1 and SMO were expressed universally across all four lines. Neither GLI1 nor GLI2
was detected in NCI-H2170. In the remaining three lines, GLI1 was expressed at a low
level, whereas high levels of GLI2 were consistently detected at both the mRNA and protein
level. To ascertain whether these cell lines represent different LSCC subtypes by mRNA
expression, gene expression profiles from CCLE (37) were analyzed. NCI-H520 and NCI-
H2170 were predicted to be classical subtype, and NCI-H226 and SK-MES-1 as secretory
subtype. Gene expression of the subtypes between the cell lines and patient tumors is
consistent over the validation gene set (Supplementary Figure S2).
shRNA knockdown of SMO produces minor effects on LSCC survival
The universal expression and the ability to target SMO with multiple available inhibitors
prompted us to investigate the importance of SMO in LSCC cells. Lentiviral mediated
expression of independent SMO shRNA constructs successfully reduced the SMO mRNA
level by 70∼90% in four cell lines (Figure 3A). However, only minor effects on cell
viability and apoptosis were observed in these cells (Figure 3B, C). SMO knockdown caused
a moderate decrease of PTCH1 mRNA in NCI-H520 and NCI-H226 (Figure 3D), but no
significant reduction of HHIP mRNA in any of four lines (Figure 3E). These data suggest a
minimal role for SMO in regulating LSCC survival via the canonical HH pathway.
Interestingly, loss of SMO did not reduce GLI2 mRNA level in three GLI-positive cell lines.
Instead, we noted a slight increase of GLI2 mRNA (Figure 3F), which may be caused by
compensatory upregulation of GLI2 by other SMO-independent mechanisms.
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Targeting GLI2 with shRNAs inhibits LSCC cell growth and induces extensive apoptosis
Since GLI1 is hardly detectable and high level of GLI2 is consistently expressed in three cell
lines and across human LSCC tumors, we focused on GLI2. Independent lentiviral-based
GLI2 shRNAs achieved satisfactory knockdown of GLI2 protein in all three GLI2-positive
lines (Figure 3G). Knockdown of GLI2 reduced the protein level of the GLI target CCND1
(Figure 3G), corresponding to a strong inhibition of cell proliferation and survival (Figure
3H). Loss of GLI2 also induced extensive apoptosis, demonstrated by elevated caspase 3/7
activity (Figure 3I), and the detection of cleaved caspase-3 and cleaved PARP (Figure 3G).
These data suggest an important role of GLI2 in regulating LSCC cell survival, raising the
possibility that GLI2 is a therapeutic target in human LSCC.
GLI inhibitor (GANT61) leads to significant growth inhibition and apoptosis, and
demonstrates greater efficacy than the SMO inhibitor (GDC-0449)
To investigate the feasibility of pharmacologically targeting SMO or GLI proteins in LSCC,
we studied the therapeutic potential of a clinically available SMO inhibitor, GDC-0449, and
a GLI inhibitor, GANT61. To maintain physiologic relevance and minimize off-target
toxicity, we assessed the efficacy of GDC-0449 and GANT61 in four LSCC cell lines at the
concentrations of 2.5, 5 and 10 μmol/L. Cells were treated in triplicate with either DMSO
control, GDC-0449 or GANT61 for 96 hours, and then assayed for viability and caspase 3/7
activation.
As Figure 4A and 4B demonstrate, GDC-0449 showed limited growth inhibition and
apoptosis induction only in NCI-H520 and NCI-H226 cells at 10 μmol/L despite the
universal expression of SMO. Consistently, GDC-0449 only caused modest reduction of
PTCH1 mRNA in NCI-H226 cells (Figure 5A). Among three GLI-positive cell lines,
GDC-0449 led to slight decrease of GLI2 mRNA in NCI-H226 and SK-MES-1 (Figure 5B),
again suggesting a minimal role of SMO in mediating HH-GLI signaling in LSCC.
In contrast, GANT61 demonstrated greater efficacy in a dose-dependent manner in all GLI-
positive cells. The originally reported IC50 of GANT61 to reduce GLI-luciferase reporter
activity is ≈5 μmol/L(29), and 5∼30 μmol/L is commonly used (29-31). In our studies, the
IC50 of growth inhibition for three GLI-positive lines was ≈5 μmol/L (Figure 4C). Both
NCI-H520 and NCI-H226 showed a 55% reduction at 5 μmol/L and 90% reduction at 10
μmol/L in cell survival. SK-MES-1 displayed approximate 40% and 60% decrease in
viability at 5 and 10 μmol/L, respectively. As expected, GANT61 exhibited little
cytotoxicity in GLI-negative NCI-H2170 cells. Consistently, increased apoptosis was seen
in GLI-positive cell lines at corresponding GANT61 concentrations: NCI-H520 (1.8∼2.3
fold), NCI-H226 (2.8∼4 fold) and SK-MES-1 (2.4∼2.6 fold), but not in GLI-negative NCI-
H2170 (Figure 4D).
Real-time PCR demonstrated significant reduction of HH downstream targets (GLI2,
PTCH1 and HHIP) in NCI-H520 with a greater decrease in NCI-H226 and SK-MES-1 in
comparison to DMSO control (Figure 5C∼E). Western analysis confirmed the reduction of
GLI2 protein in GANT61-treated cells (Figure 5F). Cleaved caspase-3 and cleaved PARP
were detected in cells receiving GANT61 (Figure 5F). The protein level of CCND1 was also
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decreased by GANT61 treatment, indicating impaired cell proliferation in addition to
increased cell death (Figure 5F).
Taken together, our results suggest that targeting HH signaling at the level of GLI proteins
may be more effective than targeting either the ligand SHH or the receptor SMO in LSCC,
potentially due to the existence of the ligand or receptor independent pathway activation.
GANT61 suppresses GLI-positive tumor progression in vivo
Currently, there are no available transgenic murine models that faithfully recapitulate human
LSCC. Recently, patient-derived xenograft models of LSCC have shown promise, but have
not yet achieved satisfactory progress. Therefore, we used a xenograft model of
representative human LSCC cell lines to determine the efficacy of GANT61 in vivo. GLI-
positive NCI-H520 or NCI-H226 and GLI-negative NCI-H2170 cancer cells were injected
subcutaneously into the right flank of immune deficient Rag1-/- mice. Mice were randomly
divided into two groups when tumors reached median size ≈250 mm3 for NCI-H520 (n=8
for each group), ≈150 mm3 for NCI-H226 (n=5 for each group) and ≈230 mm3 for NCI-
H2170 (n=5 for each group). We began treatment with either solvent control or GANT61 at
a previously described dose of 50 mg/kg (29) by intraperitoneal injection every other day.
During a 20-day treatment period, suppression of tumor growth was observed in the groups
receiving GANT61 (Figure 6A and 6B) for both NCI-H520 and NCI-H226. In contrast, no
significant difference of tumor growth was found in the NCI-H2170 xenograft (Figure 6C).
GANT61 led to a significant 40% reduction of tumor weight for both GLI-positive cell lines
in comparison to solvent control, but had no effects on GLI-negative NCI-H2170 tumors
(Figure 6D∼F), suggesting specific anti-tumor efficacy of GANT61. No adverse side
effects, such as weight loss, ulcerations, or general illness of the animals, were observed.
Real-time PCR analysis confirmed that GANT61 reduced the mRNA level of GLI target
genes PTCH1 and HHIP in NCI-H520 and NCI-H226 xenografts, but not in NCI-H2170
tumors (Figure 6G∼I).
Discussion
Aberrant HH signaling has been implicated in a diverse spectrum of human cancers.
Previous studies have reported hyperactive HH signaling in a subset of LSCC, but they
failed to address the complexity and heterogeneity of the disease. Four distinct molecular
subtypes, which have different survival outcomes, patient populations, and biological
processes, were identified by gene expression-subtype signatures (2). In the recent study of
TCGA (3), we found that the HH activation is associated with the classical subtype (∼36%
of LSCC). A consistent pattern was observed in an independent UNC microarray dataset (2).
This observation is consistent with previous immunohistochemical studies (19, 20), which
showed high activation of HH signaling in approximately 27% of LSCC patients. Among all
four subtypes, the classical subtype (2, 3) has the highest proportion of smokers and the
heaviest smoking history, as well as the greatest overexpression of three known oncogenes
on 3q26 amplicon: SOX2, TP63 and PIK3CA (2, 3).
While GLI2 was consistently highly expressed in the classical subtype, strong positive
correlations between GLI2 and the three best-known markers of the classical subtype on
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chromosome 3q were observed, together suggesting a critical role of GLI2 in LSCC, as
found in SCC in other organs (22-24). Interestingly, the expression of ligand SHH within the
classical subtype varied markedly and was not significantly different between subtypes. The
expression patterns of other two HH ligands, IHH and DHH, were similar to SHH
(Supplementary Figure S1J). These data indicate the existence of ligand-independent GLI
activation in the classical subtype. Genetic alterations, including loss of PTCH function,
constitutively active SMO, and amplification of GLI1/GLI2 have been reported to activate
downstream HH signaling independent of ligands in various cancers. Moreover, GLI
function can be modulated in a SMO-independent manner by PI3K/AKT (15), RAS-MEK
signaling (16, 17), which may contribute to the hyperactive HH-GLI signaling in LSCC in
addition to canonical HH signaling.
Recent development of multiple SMO inhibitors for human administration prompted us to
test the potential clinical application to treat LSCC patients by targeting SMO. However,
shRNAs knockdown of SMO showed only minor effects on LSCC cell survival and
apoptosis, with little effect on HH downstream target gene expression. Consistently,
GDC-0449 produced limited cytotoxicity despite the universal expression of SMO,
suggesting the existence of SMO-independent regulation of GLI signaling. The strong and
unique expression pattern of GLI2 prompted the query whether it is necessary for LSCC
tumor progression. Knockdown of GLI2 induced apoptosis and significant growth inhibition
in GLI2-positive LSCC cells, demonstrating an essential role of GLI2 in regulating cell
viability and death. Importantly, the GLI inhibitor, GANT61, effectively blocked GLI-
mediated signal transduction and suppressed tumor growth both in vitro and in vivo. Recent
studies in neuroblastoma (33) and chronic lymphocytic leukemia (34) also showed that
GANT61 effectively suppressed tumor progression in cancers insensitive to SMO inhibition.
Interestingly, amplification of GLI2 or CCND1 have been proposed as additional
mechanisms responsible for resistance to SMO inhibitors (27), and GANT61 treatment
significantly reduced expression of GLI2 and CCND1 in LSCC cells.
GANT61 is a relatively new member in the HH inhibitor family, since most known HH
pathway antagonists focus on the transmembrane activator SMO. Other readily available
agents that inhibit GLI2 are rare. Arsenic trioxide (ATO), which is FDA-approved treatment
for acute promyelocytic leukemia, has recently been described as a potent HH inhibitor.
ATO has been shown to inhibit HH signaling by inhibiting GLI2 ciliary accumulation and
promoting its degradation (38), and inhibit tumor growth in cancers with known drug-
resistant SMO mutations and in the context of GLI2 overexpression (39). Due to the
likelihood that compounds suppressing HH pathway-dependent proliferation in one cell type
may be inactive in others, the clinical relevance of ATO in LSCC treatment is currently
under investigation.
A recently emerging idea in clinical treatment is to combine several anti-tumor agents that
specifically target different signaling pathways. It has been reported that GLI function can
be modulated in a SMO-independent manner by PI3K/AKT signaling (15). Pharmacologic
inhibition of PI3K/AKT signaling reduced tumor growth in GDC-0449-resistant
medulloblastoma (27). Several inhibitors of the PI3K pathway are undergoing clinical
evaluation. PIK3CA copy number gains and loss of PTEN function are prevalent in the
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classical subtype of LSCC, where the activation of HH signaling was observed. This
coexistence raises the possibility that a combined therapy may be more beneficial than a
monotherapy to enhance efficiency and overcome drug resistance.
Treatment options for LSCC overall are disappointing. Different from standard-of-care
chemotherapy or small molecule inhibition of kinase signaling cascades, we present a
potential strategy to treat a subset of LSCC patients by targeting the GLI transcriptional
network. Our studies also highlight the need for agents that suppress GLI effectors with high
efficacy and selectivity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Targeted therapeutics for lung squamous cell carcinoma (LSCC) are currently lacking. In
this study, we have analyzed molecular subtypes of LSCC and identified overexpression
of HEDGEHOG family members in the classical subtype. In representative LSCC cell
lines, genetic deletion of SMOOTHENED (SMO) produced minor effects on cell
survival, while GLI2 knockdown greatly reduced cell viability and induced extensive
apoptosis. Using both in vitro and in vivo approaches, we evaluated therapeutic efficacy
of GDC-0449, a clinically-available SMO inhibitor as well as GANT61, a targeted GLI
inhibitor. GANT61 was significantly more effective than GDC-0449 in reduction of
proliferation and induction of apoptosis. We report SMO-independent regulation of GLI
in LSCC, and present a potential strategy of targeting GLIs to treat a subset of LSCC
patients.
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Figure 1. HH pathway components are overexpressed in the classical subtype of LSCC in the
TCGA cohort
A. Heatmap of HH signaling components. Tumor samples are displayed as columns,
grouped by gene expression subtypes. Selected HH genes are rows. Displayed genes of HH
pathway except SHH, showed highly significant association with gene expression subtype
(p<0.001) (Supplementary Table 1). B. GLI2 expression is significantly higher than GLI1
(p=4.2×10-5). C. Gene expression values were plotted according to subtypes, and the 75th
percentile of all GLI2 expression is shown as a horizontal red line. D∼F. Scatterplots of
gene expression measurements between GLI2 and SOX2 (D), TP63 (E) and PIK3CA (F).
Spearman correlation coefficients and corresponding p values were provided in
Supplementary Table 2.
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Figure 2. HH signaling components are expressed in human LSCC cell lines
A. Real-time PCR for indicated genes, with GAPDH as the quantitative control. B, Western
Blot for the SHH-GLI pathway components, with GAPDH as the loading control. Classical
subtype: NCI-H520 and NCI-H2170; Secretory subtype: NCI-H226 and SK-MES-1.
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Figure 3. SMO plays a minor role while GLI2 is required for LSCC survival in vitro
A. Change of GAPDH-normalized SMO mRNA level by real-time PCR following lentiviral
shRNA knockdown. Non-targeting shRNA control (shNT) or 2 independent shRNAs (SMO
sh1, 2, 3) targeting SMO were used in each cell line. B∼C. Measurements of viability (B)
and apoptosis (C) in cells after SMO knockdown. Data were normalized to shNT control and
represent the mean ± SD of 3 independent experiments. D∼F. Real-time PCR showing the
GAPDH-normalized mRNA level of PTCH1 (D), HHIP (E) and GLI2 (F) after SMO
knockdown. G. Western blots showing GLI2 knockdown by independent shRNAs (GLI2
sh1, 2, 3). GLI2 shRNAs significantly reduced GLI2 protein levels, in comparison to the
shNT control. GLI2 knockdown also caused induction of cleaved caspase-3, cleaved PARP
and reduction of CCND1. GAPDH was used as the loading control. A representative
Western blot from 3 independent experiments is shown. Knockdown of GLI2 in LSCC cells
significantly reduced proliferation (H) and induced apoptosis (I). Data were normalized to
shNT control and represent the mean ± SD of 3 independent experiments. (Two-tailed t test,
**: p<0.01; ***: p<0.001)
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Figure 4. GANT61 is more effective than GDC-0449 in reducing cell survival and inducing
apoptosis
A∼B. 96-hour treatment of GDC-0449 generated limited growth inhibition (A) and
apoptosis (B). Only moderate cytotoxicity was observed in NCI-H520 and NCI-H226 cells
at 10 μmol/L. C∼D. 96-hour treatment of GANT61 significantly reduced cell survival (C)
and induced extensive apoptosis (D) in all GLI-positive cell lines. GLI-negative NCI-H2170
was not affected by GANT61. Data were normalized to DMSO control and represent the
mean ± SD of 3 independent experiments. (Two-tailed t test, *: p<0.05; **: p<0.01; ***:
p<0.001)
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Figure 5. GANT61 is more efficient than GDC-0449 in suppressing the expression of GLI target
genes
A∼B. Real-time PCR of GAPDH-normalized mRNA level of PTCH1 (A) and GLI2 (B) in
cells treated with DMSO or 10 μmol/L GDC-0449 for 96 hours. C∼E. 96-hour exposure to
10 μmol/L GANT61 reduced mRNA levels of GLI targets. Gene expressions were
normalized to endogenous GAPDH in each cell line. Data represent the mean ± SD of 3
independent experiments. (Two-tailed t test, *: p<0.05; **: p<0.01; ***: p<0.001) F. 96-
hour treatment of 10 μmol/L GANT61 reduced protein levels of GLI2 and CCND1, and
induced cleaved caspase-3 and cleaved PARP. GAPDH was used as the loading control. A
representative Western blot from 3 independent experiments is shown.
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Figure 6. GANT61 treatment suppressed GLI-positive tumor progression in vivo
A∼C, Growth of NCI-H520 (A, n=8), NCI-H226 (B, n=5), and NCI-H2170 (C, n=5)
xenografts (mean ± SD). D∼F, Measurement of tumor weight at the end of treatment for
NCI-H520 (D, n=8), NCI-H226 (E, n=5), and NCI-H2170 (F, n=5). Shown is the mean ±
SD. G∼I, Quantification of PTCH1 and HHIP mRNA by real-time PCR in treated tumors
for NCI-H520 (G, n=4), NCI-H226 (H, n=5), and NCI-H2170 (I, n=5). Values were
normalized against GAPDH. Shown is the mean ± SD of independent tumors in each group.
In A∼I, data were analyzed by two-tailed t test. (*: p<0.05; **: p<0.01; ***: p<0.001, NS:
not significant.)
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